The company's breath analysis system has been tested by the Cleveland Clinic, reporting an 81% accuracy of lung cancer detection, comparable to CT scan. The system can also identify the subtype of lung cancer. Metabolomx is now testing a new, more sensitive sensor. Additionally, the company offers a colorimetric sensor array that allows identification of species or mixtures presented in exhaled breath, enabling clients to monitor their health and wellness.